International Urology and Nephrology

, Volume 51, Issue 11, pp 2045–2053 | Cite as

The relationship between R wave peak time and left ventricular mass index in patients with end-stage renal disease on hemodialysis

  • Macit KalçıkEmail author
  • Mucahit Yetim
  • Tolga Doğan
  • Barış Eser
  • İbrahim Doğan
  • Lütfü Bekar
  • Oğuzhan Çelik
  • Yusuf Karavelioğlu
Nephrology - Original Paper



Cardiovascular complications have been reported to be the main cause of mortality in patients with end-stage renal disease (ESRD). Although left ventricular hypertrophy is the most common clinical presentation of cardiac remodeling, cardiovascular complications may also include disturbances of the heart conduction system. The R wave peak time (RWPT) has been previously associated with left ventricular hypertrophy and myocardial ischemia. In this study, we aimed to investigate the relationship between RWPT and echocardiographic parameters in patients with ESRD.


This study enrolled 66 patients (29 females, age 57.2 ± 12.8 years) with ESRD, and 72 controls (37 females, age 55.3 ± 10.1 years) with similar risk factors. All patients underwent electrocardiography and transthoracic echocardiography. The RWPT was defined as the interval between the onset of the QRS complex and the peak of the R or R′ wave.


There was no significant difference in terms of clinical and demographic parameters between ESRD patients and controls. Left ventricular ejection fraction was similar between the groups. However, left atrial diameter, interventricular septal thickness, posterior wall thickness, left ventricular mass (LVM) and left ventricular mass index (LVMI) were significantly higher in patients with ESRD. Among electrocardiographic parameters, P wave and QRS complex durations and RWPT were significantly higher in patients with ESRD. Prolonged RWPT, increased LVM and LVMI were identified as associates of ESRD. Furthermore, RWPT correlated well with LVM and LVMI.


The present study demonstrated that RWPT prolonged significantly in patients with ESRD. Furthermore, prolonged RWPT has been associated with increased LVM and LVMI.


Echocardiography Electrocardiography End-stage renal disease R wave peak time 


Author contributions

All of the authors contributed to planning, conduct, and reporting of the work. All authors had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.


No funding was received for this study.

Compliance with ethical standards

Conflict of interest

All of the authors have no conflict of interest.


  1. 1.
    Parekh RS, Carroll CE, Wolfe RA, Port FK (2002) Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 141:191–197PubMedGoogle Scholar
  2. 2.
    Saeed F, Arrigain S, Schold JD, Nally JV Jr, Navaneethan SD (2019) What are the risk factors for one-year mortality in older patients with chronic kidney disease? An analysis of the cleveland clinic CKD registry. Nephron 141(2):98–104PubMedGoogle Scholar
  3. 3.
    Wang AY (2007) Cardiovascular risk factors in peritoneal dialysis patients revisited. Perit Dial Int 27(Suppl 2):S223–S227PubMedGoogle Scholar
  4. 4.
    García-López E, Carrero JJ, Suliman ME, Lindholm B, Stenvinkel P (2007) Risk factors for cardiovascular disease in patients undergoing peritoneal dialysis. Perit Dial Int 27(Suppl 2):S205–S209PubMedGoogle Scholar
  5. 5.
    Hampl H, Riedel E (2009) Cardiac disease in the dialysis patient: good, better, best clinical practice. Blood Purif 27:99–113PubMedGoogle Scholar
  6. 6.
    Rodriguez M, Lorenzo V (2009) Progress in uremic toxin research: parathyroid hormone, a uremic toxin. Semin Dial 22:363–368PubMedGoogle Scholar
  7. 7.
    MacLeod AG, Wilson FN, Barker PS (1930) The form of the electrocardiogram. I. Intrinsicoid electrocardiographic deflections in animals and man. Exp Biol Med 27:586–587Google Scholar
  8. 8.
    Pérez-Riera AR, de Abreu LC, Barbosa-Barros R, Nikus KC, Baranchuk A (2016) R-peak time: an electrocardiographic parameter with multiple clinical applications. Ann Noninvasive Electrocardiol 21:10–19PubMedGoogle Scholar
  9. 9.
    Holland RP, Brooks H (1976) The QRS complex during myocardial ischemia. An experimental analysis in the porcine heart. J Clin Invest 57:541–550PubMedPubMedCentralGoogle Scholar
  10. 10.
    Rencüzoğulları I, Çağdaş M, Karakoyun S et al (2018) The association between electrocardiographic R wave peak time and coronary artery disease severity in patients with non-ST segment elevation myocardial infarction and unstable angina pectoris. J Electrocardiol 51(2):230–235PubMedGoogle Scholar
  11. 11.
    Çağdaş M, Karakoyun S, Rencüzoğullari İ et al (2017) Relationship between R-wave peak time and no-reflow in ST elevation myocardial infarction treated with a primary percutaneous coronary intervention. Coron Artery Dis 28:326–331PubMedGoogle Scholar
  12. 12.
    Scharer K, Schmidt KG, Soergel M (1999) Cardiac function and structure in patients with chronic renal failure. Pediatr Nephrol 13:951–965PubMedGoogle Scholar
  13. 13.
    McCullough PA, Assad H (2012) Diagnosis of cardiovascular disease in patients with chronic kidney disease. Blood Purif 33:112–118PubMedGoogle Scholar
  14. 14.
    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305PubMedPubMedCentralGoogle Scholar
  15. 15.
    Saran R, Robinson B, Abbott KC et al (2017) US renal data system 2016 annual data report: epidemiology of Kidney Disease in the United States. Am J Kidney Dis 69(3 Suppl 1):A7–A8PubMedPubMedCentralGoogle Scholar
  16. 16.
    Eckardt KU (1999) Cardiovascular consequences of renal anaemia and erythropoietin therapy. Nephrol Dial Transpl 14:1317–1323Google Scholar
  17. 17.
    Juan-Garcia I, Puchades MJ, Sanjuan R et al (2012) Echocardiographic impact of hydration status in dialysis patients. Nefrologia 32:94–102PubMedGoogle Scholar
  18. 18.
    Poulikakos D, Ross L, Recio-Mayoral A et al (2014) Left ventricular hypertrophy and endothelial dysfunction in chronic kidney disease. Eur Heart J Cardiovasc Imaging 15:56–61PubMedGoogle Scholar
  19. 19.
    Ky B, Shults J, Keane MG et al (2013) FGF23 modifies the relationship between vitamin D and cardiac remodeling. Circ Heart Fail 6:817–824PubMedGoogle Scholar
  20. 20.
    London GM, Fabiani F, Marchais SJ et al (1987) Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. Kidney Int 31:973–980PubMedGoogle Scholar
  21. 21.
    Berk BC, Fujiwara K, Lehoux S (2007) ECM remodeling in hypertensive heart disease. J Clin Invest 117:568–575PubMedPubMedCentralGoogle Scholar
  22. 22.
    Kahan T, Bergfeldt L (2005) Left ventricular hypertrophy in hypertension: its arrhythmogenic potential. Heart 91:250–256PubMedPubMedCentralGoogle Scholar
  23. 23.
    Paoletti E, De Nicola L, Gabbai FB et al (2016) Associations of left ventricular hypertrophy and geometry with adverse outcomes in patients with CKD and hypertension. Clin J Am Soc Nephrol 11:271–279PubMedGoogle Scholar
  24. 24.
    Eckardt KU, Scherhag A, Macdougall IC et al (2009) Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. J Am Soc Nephrol 20:2651–2660PubMedPubMedCentralGoogle Scholar
  25. 25.
    Paoletti E, Specchia C, Di Maio G et al (2004) The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. Nephrol Dial Transpl 19:1829–1834Google Scholar
  26. 26.
    Tsao CW, Gona PN, Salton CJ et al (2015) Left ventricular structure and risk of cardiovascular events: a Framingham Heart Study cardiac magnetic resonance study. J Am Heart Assoc 4(9):e002188PubMedPubMedCentralGoogle Scholar
  27. 27.
    Herzog CA, Asinger RW, Berger AK et al (2011) Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: improving global outcomes (KDIGO). Kidney Int 80:572–586PubMedGoogle Scholar
  28. 28.
    Ritz E (2009) Left ventricular hypertrophy in renal disease: beyond preload and afterload. Kidney Int 75:771–773PubMedGoogle Scholar
  29. 29.
    Martin LC, Franco RJ, Gavras I et al (2004) Association between hypervolemia and ventricular hypertrophy in hemodialysis patients. Am J Hypertens 17:1163–1169PubMedGoogle Scholar
  30. 30.
    McRae JM, Levin A, Belenkie I (2006) The cardiovascular effects of arteriovenous fistulas in chronic kidney disease. A cause for concern? Semin Dial 19:349–352Google Scholar
  31. 31.
    Gross ML, Ritz E (2008) Hypertrophy and fibrosis in the cardiomyopathy of uremia—beyond coronary heart disease. Semin Dial 21:308–318PubMedGoogle Scholar
  32. 32.
    Steigerwalt S, Zafar A, Mesiha N, Gardin J, Provenzano R (2007) Role of aldosterone in left ventricular hypertrophy among African–American patients with end-stage renal disease on hemodialysis. Am J Nephrol 27:159–163PubMedGoogle Scholar
  33. 33.
    Di Lullo L, Gorini A, Russo D, Santoboni A, Ronco C (2015) Left ventricular hypertrophy in chronic kidney disease patients: from pathophysiology to treatment. Cardiorenal Med. 5(4):254–266PubMedPubMedCentralGoogle Scholar
  34. 34.
    Savard P, Rouleau JL, Ferguson J et al (1997) Risk stratification after myocardial infarction using signal-averaged electrocardiographic criteria adjusted for sex, age, and myocardial infarction location. Circulation 96:202–213PubMedGoogle Scholar
  35. 35.
    Shenkman HJ, Pampati V, Khandelwal AK et al (2002) Congestive heart failure and QRS duration: establishing prognosis study. Chest 122:528–534PubMedGoogle Scholar
  36. 36.
    Grant RP, Dodge HT (1956) Mechanisms of QRS complex prolongation in man; left ventricular conduction disturbances. Am J Med 20:834–852PubMedGoogle Scholar
  37. 37.
    Hamilin RL, Pipers FS, Hellerstein HK, Smith CR (1968) QRS alteration immediately following production of left ventricular free wall ischemia in dogs. Am J Physiol 215:1032–1040Google Scholar
  38. 38.
    Ozer N, Aytemir K, Atalar E et al (2000) P wave dispersion in hypertensive patients with paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 23:1859–1862PubMedGoogle Scholar
  39. 39.
    Turhan H, Yetkin E, Senen K et al (2002) Effects of percutaneous mitral balloon valvuloplasty on P-wave dispersion in patients with mitral stenosis. J Cardiol 89(5):607–609Google Scholar
  40. 40.
    Turhan H, Yetkin E, Atak R et al (2003) Increased P-wave duration and P-wave dispersion in patients with aortic stenosis. Ann Noninvasive Electrocardiol 8(1):18–21PubMedGoogle Scholar
  41. 41.
    Senen K, Turhan H, Riza Erbay A et al (2004) P-wave duration and P-wave dispersion in patients with dilated cardiomyopathy. Eur J Heart Fail 6:567–569PubMedGoogle Scholar
  42. 42.
    Boles U, Almuntaser I, Brown A, Murphy RR, Mahmud A, Feely J (2010) Ventricular activation time as a marker for diastolic dysfunction in early hypertension. Am J Hypertens 23(7):781–785PubMedGoogle Scholar
  43. 43.
    Mitsnefes MM, Kimball TR, Kartal J et al (2005) Cardiac and vascular adaptation in pediatric patients with chronic kidney disease: role of calcium-phosphorus metabolism. J Am Soc Nephrol 16:2796–2803PubMedGoogle Scholar
  44. 44.
    Jono S, Nishizawa Y, Shioi A, Morii H (1997) Parathyroid hormone related peptide as a regulator of vascular calcification. Its inhibitory action on in vitro calcification by bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 17:1135–1142PubMedGoogle Scholar
  45. 45.
    Lipscombe D (2002) L-type calcium channels. High and new lows. Circ Res 90:933–935PubMedGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Department of Cardiology, Faculty of MedicineHitit UniversityÇorumTurkey
  2. 2.Department of Nephrology, Faculty of MedicineHitit UniversityÇorumTurkey
  3. 3.Department of CardiologyMuğla Sıtkı Koçman University Training and Research HospitalMuğlaTurkey

Personalised recommendations